Vitex Pharmaceuticals is a wholly Australian-owned and family-operated company established in 1989. Founded and operated by the Chami family, Vitex has become one of Australia’s leading manufacturers of high-quality complementary medicine.
Vitex delivers solutions from concept to shelf to help companies of all sizes meet their development and manufacturing needs at any stage or scale. The company provides a combination of unparalleled best-in-class quality, reliability and compliance—underscored by a long-standing reputation for scientific and technical excellence acknowledged by regulatory authorities around the world.
As a contract manufacturer of complementary medicine (also known as nutraceuticals, vitamins, minerals, herbal and nutritional supplements), Vitex offers comprehensive and innovative solutions for leading brands and private labels including concept development, regulatory compliance, quality assurance, manufacturing, packaging and distribution.
Vitex Pharmaceuticals is proud of its entrepreneurial spirit, legacy of quality and steadfast growth over the years, which has seen it attain a leading position in key international markets.
With full-service manufacturing and packaging capabilities, Vitex collaborates closely with clients and regulatory authorities to ensure it is at the forefront of the global therapeutic goods industry. Unlike other contract manufacturers, Vitex has the agility, flexibility and expertise to ensure its clients can adapt and deliver products first to market.
Having built a reputation for excellence in quality, operational reliability, integrity and innovation of products and services, Vitex is well positioned to deliver meaningful and sustainable long-term value for its partners around the world.
Pursuing quality and innovation
Customers working with Vitex Pharmaceuticals have access to extensive commercial capabilities, scale and capacity; a fully integrated, $100 million best-in-class Sydney facility; a wide spectrum of dosage forms manufactured on the latest state-of-art equipment; and a vision predicated on quality, innovation and integrity.
The acquisition of custom-designed, technologically advanced equipment in 2017 has been a core advantage for the company and a key component of its innovation strategy. Vitex specifically engineered additional efficiencies into the equipment to ensure greater output, leading to faster turnaround times and greater speed to market than its competition.
Vitex is exploring ways to speed the recruitment and training of new employees to meet strong export demand. With a current workforce of 130 people, the manufacturing plant is expected to grow its numbers to over 400.
The 2,500 square metre research and development laboratory will allow brands, universities, and institutes to conduct research, develop new products, pilot new manufacturing, and facilitate clinical trials. Vitex has shown that innovative manufacturers maintaining the highest quality standards can achieve enormous success in national and international markets.